Evidence map›Paper›PMID 36802795›Full record

ArticleThe British journal of radiology2023

Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy.

Ting-Fu Hsu, Wei-Chou Chang, Ping-Ying Chang, Hsuan-Hwai Lin, Pin-Ko Chen, Kai-Hsiang Ko, Sung-Hua Chiu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ting-Fu HsuDepartment of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Wei-Chou ChangDepartment of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Ping-Ying ChangDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Hsuan-Hwai LinDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Pin-Ko ChenDepartment of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Kai-Hsiang KoDepartment of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Sung-Hua ChiuDepartment of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.ORCID 0000-0003-1118-5541
Tri-Service General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy of drug-eluting beads loaded with irinotecan (DEBIRI) in colorectal cancer (CRC) patients with synchronous liver-only metastases non-responsive to bevacizumab-based chemotherapy (BBC).

methodsFifty-eight patients were enrolled in this study. Treatment response to BBC and DEBIRI were determined by the morphological criteria and Choi's criteria, respectively. Progression-free survival (PFS) and overall survival (OS) were recorded. The correlation between pre-DEBIRI CT parameters and treatment response to DEBIRI was analyzed.

resultsCRC patients were divided into the BBC responsive group (R group) (

conclusionIn CRC patients, DEBIRI can achieve acceptable objective response for liver metastases non-responsive to BBC. However, this locoregional control does not prolong survival. The pre-DEBIRI CER can predict OR in these patients. ADVANCES IN KNOWLEDGE: DEBIRI can act as an acceptable locoregional management in CRC patients with liver metastases non-responsive to BBC, and the pre-DEBIRI CER is a potential indicator of locoregional control.

Indexed as

Antineoplastic Agents, PhytogenicChemoembolization, TherapeuticColorectal NeoplasmsLiver NeoplasmsBevacizumabCamptothecinHumansIrinotecanTreatment OutcomeAntineoplastic Agents, PhytogenicBevacizumabCamptothecinIrinotecan

Identifiers

PMID36802795
PMCPMC10161911
OpenAlexW4321371652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.